Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
|
|
- Brianna Booth
- 5 years ago
- Views:
Transcription
1 Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma
2 Colorectal cancer 3 rd most common cancer worldwide Approximately 25% of patients present with metastatic colorectal cancer (mcrc) Metastatic disease develops in 30-45% of newly diagnosed patients Treatment is typically by surgery and chemotherapy Now includes EGFR targeted monoclonal antibodies e.g. cetuximab & panitumumab Karapetis, NEJM, 2009
3 Key Drivers in Colorectal Cancer RAS PI3K RAF Normanno et al. Nat Rev Clin Oncol, 200
4 RAS, RAF and PIK3CA Mutations in Colorectal Cancer Mutation frequency KRAS: 40% NRAS: 3% BRAF: 5% PIK3CA: 15% BRAF and KRAS/NRAS mutations are mutually exclusive KRAS and NRAS mutations are mutually exclusive De Roock, Lancet Oncol 2010
5 K-RAS Status and Prognosis in CRC RASCAL I. KRAS mutation associated with increased risk of recurrence and death (1) RASCAL II. RASCAL II (2001) confirmed but only in Dukes C (Stage 3) tumors (2) posthoc PETACC-3, EORTC 40993, SAKK KRAS mutation was not a prognostic marker (3) posthoc PETACC-8. MSS, KRAS mut and BRAF mut associated with worse outcomes 1. Andreyev HJ, J Natl Cancer Inst Andreyev HJ et al. Br J Cancer. 2001
6 Is KRAS Gene Mutation a Prognostic Factor for Colorectal Cancer: A Systematic Review and Meta-analysis. Ren, JiaoJiao; Li, GuangXiao; Ge, Jie; Li, Xia; Zhao, YaShuang STUDY SELECTION: The prognostic value of KRAS gene mutations was examined in patients with colorectal cancer who did not receive preoperative chemotherapy or radiation. After exclusion of duplicate and irrelevant studies, 23 eligible published studies that included 25 sets of data were finally retrieved for the metaanalysis. RESULTS: The pooled HR for the association between KRAS gene mutations and overall survival in patients with colorectal cancer was 1.04 (95% CI: , p = 0.11). Subgroup analysis showed significant reductions in the overall survival associated with mutations at KRAS codon 12, the articles that reported HR directly, and the studies published before and after 2005, although publication bias was present. All the associations disappeared after adjustment with the trimand-fill method. The pooled HR of 3 studies examining mutations at KRAS codon 13 was 1.47 (95% CI: , p = 0.02), and no publication bias was observed. No significant association was observed in different study regions. CONCLUSIONS: Overall KRAS gene mutations seem not to correlate with the prognosis of patients with colorectal cancer. The association remains to be confirmed with a more precise analysis of a large sample. JJ Ren, Diseases of the Colon & Rectum.
7 K-RAS Status and Prognosis in mcrc Modest DP, Ann Oncol
8 K-RAS Status and Prognosis in mcrc Modest DP, Ann Oncol
9 K-Ras mutation status has been always considered a dichotomic information, so far. BUT In the cancers genetic heterogeneity scenario is important to take into account the percentage of K-Ras mutated cells into the tumour Mutation rate defined as a measure of the rate of mutant alleles
10
11 Study Design Type: Multicentric Retrospective Study Aim: Evaluation of the prognostic significance of K-RAS mutation rate in mcrc patients treated with bevacizumab-containing chemotherapy Network: Policlinico Universitario Campus Bio-Medico di Roma Azienda Ospedaliero-Universitaria Pisana Ospedale Niguarda Ca Granda, Milano Oncologia Medica, Università di Palermo Università Cattolica del Sacro Cuore, Roma Azienda Ospedaliero-Universitaria, Udine Università G. D Annunzio, Chieti Methods : Pirosequencing on FFPE tumor tissue (>60% tumor cells) Statistical analyses: Univariate Analyses Kaplan-Meier (KRAS Mutation Rate dichotomized >40% vs <40%) Multivariate Analyse Cox-regression analyses (KRAS Mutation Rate as continue variable) Endpoints : PFS and OS
12 Methods: Patients population Absolute number Number of evaluable patients Available data about Bevacizumab-chemotherapy Gender (male/female) 144/ /43.4 K-Ras determination (primary vs met) 194/ /26.2 Second Line % Third Line Irinotecan based/oxaliplatin based 201/ /23.6 Number of involved organs or more Cumulative response rate (cpr + ccr) 49% - PFS 8.25 months OS 26 months B.Vincenzi, Oncotarget 2016
13 Methods: Patients population Diagram of the patients enrolled 397 patients (K-Ras mutated/beva in 1line) 92 out (<60% cancer cells) 305 patients 27 out (incomplete FUP data) 278 patients 15 out (miscellaneous) 263 evaluable patients B.Vincenzi, Oncotarget 2016
14 Laboratory methods FFPE tumor samples selection and dissection by pathologist (presence of tumor cells at least 60%) RNA extraction and purification Pyrosequencing analysis of K-Ras status (codons 12, 13, 61, 117 and 146)
15 Results: univariate survival analysis POPULATION (K-Ras mutated codons) Codon 12, all patients (pts) Codon 12, Pts with >40% vs 40% mutant alleles PFS(95% CI) [mts] OS(95% CI) [mts] 8.25 (95% CI: ) 28 (95% CI: ) 7.45 (95% CI: ) vs 9.45 (95% CI: ) 23 (95% CI: ) vs 31 (95% CI: ) Codon 13, all patients (pts) 8.90 (95% CI: ) 21 (95% CI: ) Codon 13, Pts with >40% vs 40% mutant alleles Rare codons, all patients (pts) Rare codons, Pts with >40% vs 40% mutant alleles All K-Ras mutated codons, Pts with >40% vs 40% mutant alleles 7.25 (95% CI: ) vs (95% CI: ) 5.50 (95% CI: ) 5.5 (95% CI: ) vs 7.25 (95% CI: ) 7.25 (95% CI: ) vs 9 (95% CI: ) 17 (95% CI: ) vs 24 (95% CI: ) 21 (95% CI: ) vs 31 (95% CI: ) Log Rank P P=0.000 P=0.002 A mutation rate higher than 40% in all codons analyzed was significantly associated with a worse survival B.Vincenzi, Oncotarget 2016
16 Results: Kaplan-Meyer analysis B.Vincenzi, Oncotarget 2016
17 Results: multivariate survival analysis Survival Analysis (unadjusted) PFS HR: 0.63 ( ) P<0.001 OS HR: 0.66 ( ) P=0.004 Survival Analysis (adjusted) HR: 0.67 ( ) P=0.003 HR: 0.66 ( ) P=0.012 Codon 12 Codon 13 Rare codons HR: 0.71 ( ) P=0.003 HR: 0.62 ( ) P=0.066 HR: 0.19 ( ) P=0.397 HR: 0.69 ( ) P=0.011 HR: ( ) P=0.179 HR: 0.43 ( ) P=0.397 Only codon 12 mutation rate remained significantly associated with PFS and OS in multivariate analyses B.Vincenzi, Oncotarget 2016
18 Conclusions Despite of the well known importance of K-Ras mutations as predictive factor to anti-egfr drugs administration, there is no consensus about the prognostic value of mutational status of K-Ras in CRC patients One of the reasons of these inconclusive results can be also attributed to cancer heterogeneity The use of pyrosequencing technology allow us to identify a novel parameter the mutation rate defined as the measure of the rate of mutant alleles We demonstrated for the first time a correlation between the K-Ras mutation rate (presence of more or less than 40% mutant alleles) in advanced CRC population treated with bevacizumab containing first-line regimens The limit of the study derives from its retrospective nature, thus our data need to be confirmed in a validation prospective set The cut-off of 40% (median value) was arbitrarily chosen and should be
19
KRAS G13D mutation testing and anti-egfr therapy
KRAS G13D mutation testing and anti-egfr therapy KRAS G13D mutation and anti-egfr therapy Current data do not support a need to specifically identify this mutation for assessing anti-egfr eligibility in
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationMEDICAL POLICY. SUBJECT: GENOTYPING - RAS MUTATION ANALYSIS IN METASTATIC COLORECTAL CANCER (KRAS/NRAS) POLICY NUMBER: CATEGORY: Laboratory
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationRelated Policies None
Medical Policy MP 2.04.53 BCBSA Ref. Policy: 2.04.53 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationPublished Ahead of Print on November 26, 2012 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on November 26, 202 as.200/jco.202.45.492 The latest version is at http://jco.ascopubs.org/cgi/doi/.200/jco.202.45.492 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationDENOMINATOR: Adult patients with metastatic colorectal cancer who have a RAS (KRAS or NRAS) gene mutation
Quality ID #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) 4 with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy Domain:
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationClinical Trials in the Era of Personalised Medicine and Biomarkers. Chris Karapetis New Zealand Society of Oncology Conference 2 nd July 2012
Clinical Trials in the Era of Personalised Medicine and Biomarkers Chris Karapetis New Zealand Society of Oncology Conference 2 nd July 2012 The EGFR Signaling Network is Vast and Complicated EGFR activation
More informationIf multiple KRAS mutation tests have been performed, refer to the most recent test results.
Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy
More informationHot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon
Convegno Nazionale AIOM Giovani 2018 News in Oncology Hot Topic in tema di neoplasie del Colon: Durata ottimale della chemioterapia adiuvante nei tumori del Colon Daniele Rossini U.O. di Oncologia Medica
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Variant Analysis
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationWorst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma
JBUON 2018; 23(4): 925-935 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Worst outcomes according to RAS mutation variants: an analysis in patients
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationKRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Policy Number: 2.04.53 Last Review: 5/2018 Origination: 1/2011 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationAvailable at journal homepage:
European Journal of Cancer (212) 48, 1466 1475 Available at www.sciencedirect.com journal homepage: www.ejconline.com Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationRESEARCH ARTICLE. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
RESEARCH ARTICLE Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Yusuke Sasaki 1,2, Tetsuya Hamaguchi 1 *, Yasuhide Yamada
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationDOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT?
DOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT? By: Dr. Dominik Modest, Medical Department III, Hospital of the University of Munich, Germany Dr. Andrea Sartore-Bianchi, Niguarda Cancer Center,
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationPage: 1 of 17. KRAS, NRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer
Page: 1 of 17 Last Review Status/Date: March 2015 Analysis in Metastatic Colorectal Cancer Description This policy summarizes the evidence for using tumor cell KRAS, NRAS and BRAF mutational status as
More informationColon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome
Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &
More informationPlasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc)
Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc) Authors: Andrea Petricca Mancuso, Veronica Varchetta, Fabrizio
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationOncologist. The. Gastrointestinal Cancer
The Oncologist Gastrointestinal Cancer The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationCANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS
AIOM Meeting Milan, 26 February 2016 CANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS Lisa Salvatore Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa My Agenda The metronomic
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationReview of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups. Chemotherapy and targeted agents in 1st line
ESMO Preceptorship Programme Colorectal Cancer Valencia, 18th May 2018 Review of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups Chemotherapy and targeted agents
More informationCetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience
JBUON 2016; 21(1): 70-79 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Cetuximab in third-line therapy of patients with metastatic colorectal
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationREVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 REVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER Andrés Cervantes Professor of Medicine Strategic changes
More informationE importante t che il chirurgo conosca il profilo molecolare del carcinoma del colon?
E importante t che il chirurgo conosca il profilo molecolare del carcinoma del colon? Giuseppe Aprile Dipartimento di Oncologia Dipartimento di Oncologia Azienda Ospedaliero-Universitaria - Udine Dr. Giuseppe
More informationAnnals of Oncology Advance Access published August 12, 2014
Annals of Oncology Advance Access published August 12, 2014 1 Extended RAS mutations and anti-egfr monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled
More informationColon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationRAS and BRAF in metastatic colorectal cancer management
Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical
More informationMetastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab. Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014
Metastatik Kolorektal Kanser Tedavisinde Yeni Biyobelirteçler Sonrası Panitumumab Prof. Dr. N. Faruk Aykan Antalya 22 Mart 2014 1952-1953 St. Louis, ABD Kinase growth factor pathway Activated receptor
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationEXAMPLE. ratio (%) Contraindication for treatment with panitumumab or cetuximab
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999 Requested 17 May
More information2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationOHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer
OHTAC Recommendation KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer Presented to the Ontario Health Technology Advisory Committee in August, 2010 December 2010 Issue Background In February
More informationEGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
1432 EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab ELISA CHIADINI 1, EMANUELA SCARPI 2, ALESSANDRO PASSARDI 3, DANIELE CALISTRI 1, MARTINA VALGIUSTI 3,
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More information4. Aflibercept showed significant improvement in overall survival (OS), the primary
Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin
More informationPersonalised Medicine
Personalised Medicine Panacea or Pandora s box? Dr Tom Lillie Oncology Therapeutic Area Head Amgen October 2012 Amgen is the world s leading biotechnology company employs more than 17,000 staff in 39 countries
More informationBRAF: dal melanoma alla HCL
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica BRAF: dal
More informationK-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC. Monica Bertagnolli, MD. CRA Continuing Education, November 2008
K-Ras mutational status and response to EGFR inhibitors for treatment of advanced CRC Monica Bertagnolli, MD CRA Continuing Education, November 2008 The Ras Oncogene Kirsten and Harvey: 1964 Identification
More informationColorectal Cancer: Critical review
AIOM POST-ASCO 2018 Updates and Review from Chicago Milano, June 15-16, 2018 Colorectal Cancer: Critical review Alfredo Falcone, MD Department of Oncology and Translational Medicine University of Pisa
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationUnderstanding predictive and prognostic markers
Understanding predictive and prognostic markers Professor Aimery de Gramont Chairman of ARCAD Foundation and GERCOR, Paris FRANCE Understanding predictive and prognostic markers Aimery de Gramont Prognostic
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationThe ESMO consensus conference on metastatic colorectal cancer
ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 3 September 2014 VECTIBIX, 20 mg/ml, concentrate for solution for infusion B/1 5 ml vial (CIP: 34009 571 818 5 7)
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More information